Research objective: to estimate results of treatment of patients with the localized form of a cancer of a prostate at a combination of a transurethral resection (TURP) and HIFU of an ablation. Objects and research methods: From February, 2009 to February, 2014 of 100 patients with the localized form of a cancer of a prostate were selected for research: 26 patients were included into HIFU and 74 group in group of the combined treatment (TURP+HIFU). Selection criteria for HIFU ablation were the localized cancer of a prostate concerning which earlier it wasn't carried out treatments, and level of a PSA at the time of statement of the diagnosis 15 ng/ml. All patients corresponding to these by criteria, were considered as candidates for treatment and inclusion in the analysis. The nadir and stability of PSA, the histologic conclusion, IPSS, quality of life and complication were estimated at time of postoperative supervision. Results: Statistically significant influence of a combination TURP+HIFU for the term of transurethral drainage of a bladder (a median of 40 days against 7 days), incontience frequency (15.4% against 6.9%), infections of urinary ways (47.9% against 11.4%) and IPSS change during the postoperative period (on the average 8.91 against 3.37) is noted. During the short period of supervision it wasn't observed considerable changes in relation to efficiency: in HIFU group the frequency of repeated sessions made 25%, in TUR/HIFU group 4%. Conclusion: HIFU therapy is modern, minimum invasive method of a cancer therapy of a prostate. The combination of a transurethral resection and HIFU ablation significantly reduces the frequency of the complications connected with treatment. Maintaining the patient after combined TURP and HIFU ablation is comparable with maintaining the patient after usual TURP.
Popkov V.M., Fomkin R.N., Blyumberg B.l., Shatylko T.V., Sedova L.N., Abramova E.P. Combination of the transurethral resection and prostate HIFU ablation at treatment of the localized cancer // Saratov Journal of Medical Scientific Research, Vol. 10, Issue 3, 2014, pp. 450-455

Research objective: Creation of mathematical prognosis of model of local relapsing tumors in patients with prostate cancer after treatment by high-intensive focused ultrasound (HIFU). Objects and Research Methods: Results of treatment are estimated at 102 patients with morphologically localized prostate cancer proved at biopsy. For the purpose to analyze interrelation of prognostic factors and postoperative morphological research of prostate control biopsies after HIFU ablation with frequent development of relapses comparative statistical research of received data has been conducted. For construction of mathematical models of relapse prognosis after HIFU of prostates two methods of mul-tifactorial analysis of the data have been used: the discriminant analysis and logistical regress. Results: While planning treatment of patients after HIFU ablation of prostates it has been necessary to estimate morphological risk factors of local relapse of a neoplasm such as preoperative level of serum PSA, the sum of Gleason, severity of disease, presence of lymphovascular and perineural invasion. The offered formulas are worth while using in revealing of probability of development of relapses. The comparative analysis of mathematical models has showed that accuracy of prognosis of results of HIFU of prostates is high enough.
Popkov V.M., Fomkin R.N., Blumberg B.I. Возможности прогнозирования рецидива рака простаты после HIFU-аблации с помощью математического моделирования // Saratov Journal of Medical Scientific Research, Vol. 9, Issue 2, 2013, pp. 314-320

Research objective: To study the role of prognostic factors in the estimation of risk development of recurrent prostate cancer after treatment by high-intensive focused ultrasound (HIUF). Objects and Research Methods: The research has included 102 patients with morphologically revealed localized prostate cancer by biopsy. They have been on treatment in Clinic of Urology of the Saratov Clinical Hospital n.a. S. R. Mirotvortsev. 102 sessions of initial operative treatment of prostate cancer by the method of HIFU have been performed. The general group of patients (n=102) has been subdivided by the method of casual distribution into two samples: group of patients with absent recurrent tumor and group of patients with the revealed recurrent tumor, by morphological research of biopsy material of residual prostate tissue after HIFU. The computer program has been used to study the signs of outcome of patients with prostate cancer. Results: Risk of development of recurrent prostate cancer has grown with the PSA level raise and its density. The index of positive biopsy columns <0,2 has shown the recurrence of prostate cancer in 17% cases while occurrence of prostate cancer in 59% cases has been determined by the index of 0,5 and higher. The tendency to obvious growth of number of relapses has been revealed by the sum of Glison raise with present perineural invasion. Cases of recurrent prostate cancer have been predominant in patients with lymphovascular invasions. In conclusion it has been worked out that the main signs of recurrent prostate cancer development may include: PSA, PSA density, the sum of Glison, lymphovascular invasion, invasion.
Popkov V.M., Fomkin R.N., Blyumberg B.I. Prognostic factors in the estimation of HIFU treatment efficiency in patients with localized prostate cancer // Saratov Journal of Medical Scientific Research, Vol. 9, Issue 1, 2013, pp. 116-121

Research objective: to estimate efficiency of treatment of prostate cancer using high-intensive focused ultrasound on the basis of laboratory analysis of postoperative level prostate-specific antigen (PSA). Objects of research. Objects of research consisted of 110 patients treated in urological clinic of Hospital n.a. S. R. Mirotvortsev (Saratov State Medical University) during the period February, 2009 — March, 2012. Patients took 110 sessions of primary operative treatment of prostate cancer by HIFU therapy method. Technique and research methods. Concentration of PSA in blood changed in all patients every 1,5 month within 6 months after operation, irrespective of its kind (including after repeated HIFU), further — after every 3 month till one year, and later on after 6 months. We were guided by references of the International Consensus, which considers PSA level more than 0,5 ng/ml in blood after 3 months of treatment to be unsatisfactory result. We also headed for PSA level before treatment and oncological risk degree. Results. Median nadir formed 0,5 ng/ml PSA by 3 months after treatment. Patients demonstrated different indicators of PSA dynamics depending on oncological risk, stage and hormonal therapy management. Patients with low oncological risk had initially lower PSA concentration, further PSA concentration reached nadir level faster. At patients with widespread forms of prostate cancer accurate dependence of PSA concentration according to prevalence of process was traced. Time of PSA nadir amount did not differ and was marked as 12-14 weeks on average. At patients received hormonal therapy, lower value of PSA nadir was marked. The conclusion. Monitoring of PSA concentration (PSA nadir by 3 months, dynamics of PSA concentration change) is of great importance in early revealing of relapse after prostate HIFU therapy. High level of PSA nadir and PSA growth according to time period are important prognostic factors.
Popkov V.M., Fomkin R.N., Blyumberg B.I. Postoperative monitoring of prostate-specific antigen (PSA) after treatment with high-intensive focused ultrasound (HIFU // Saratov Journal of Medical Scientific Research, Vol. 8, Issue 4, 2012, pp. 1001-1007

Increasing interest devoted to technology of high intensity focused ultrasound (high-intensity focused ultrasound, HIFU), basically, is explained by a wide spectrum of potential fields of application at minimum invasiveness of the given method. In oncourology HIFU is applied in prostate and kidney cancer. In case of tumors of renal parenchyma the given technique is being clinically tested, while HIFU is currently used in the practice of European oncourologists in treatment of prostate cancer. The majority of the references describing the results of HIFU application in prostate cancer is based on data of a number of clinical observations. It has been proved that HIFU is a possible method of treatment of highly — and moderate-differentiated tumors, and local relapses after remote radial therapy.
Popkov V.M., Fomkin R.N., Blyumberg B.I. High intensity focused ultrasound (HIFU) as the alternative method of treatment of oncourological diseases // Saratov Journal of Medical Scientific Research, Vol. 8, Issue 4, 2012, pp. 989-995